This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2017
  • /
  • 01
  • /
  • UK's NICE recommends use of Cimzia (certolizumab p...
Drug news

UK's NICE recommends use of Cimzia (certolizumab pegol) in active psoriatic arthritis- UCB

Read time: 1 mins
Last updated:28th Jun 2017
Published:8th Jan 2017
Source: Pharmawand

The National Institute for Health and Care Excellence is supporting use of Cimzia (certolizumab pegol), from UCB, alone, or in combination with methotrexate, for adults with active psoriatic arthritis if the person has had a TNF-alpha inhibitor but their disease has stopped responding after the first 12 weeks, and the drug is provided under the conditions of a patient access scheme.

Use should also follow existing NICE guidance psoriatic arthritis treatment with etanercept (Pfizer's Enbrel), infliximab (MSD's Remicade, Napp Pharmaceuticals' Remsima, and Hospira's Inflectra) and adalimumab (AbbVie's Humira), the Institute noted.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.